BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19435788)

  • 1. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer.
    Kuruma H; Kamata Y; Takahashi H; Igarashi K; Kimura T; Miki K; Miki J; Sasaki H; Hayashi N; Egawa S
    Am J Pathol; 2009 Jun; 174(6):2044-50. PubMed ID: 19435788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
    Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
    Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1.
    Ma F; Song H; Guo B; Zhang Y; Zheng Y; Lin C; Wu Y; Guan G; Sha R; Zhou Q; Wang D; Zhou X; Li J; Qiu X
    Oncotarget; 2015 Jul; 6(19):17404-16. PubMed ID: 25965817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
    Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
    Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review).
    Jariwala N; Rajasekaran D; Srivastava J; Gredler R; Akiel MA; Robertson CL; Emdad L; Fisher PB; Sarkar D
    Int J Oncol; 2015 Feb; 46(2):465-73. PubMed ID: 25405367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells.
    Cappellari M; Bielli P; Paronetto MP; Ciccosanti F; Fimia GM; Saarikettu J; Silvennoinen O; Sette C
    Oncogene; 2014 Jul; 33(29):3794-802. PubMed ID: 23995791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
    Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
    JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of Metadherin-SND1 interaction in colon cancer.
    Wang N; Du X; Zang L; Song N; Yang T; Dong R; Wu T; He X; Lu J
    Mol Biol Rep; 2012 Dec; 39(12):10497-504. PubMed ID: 23065261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis.
    Tsuchiya N; Ochiai M; Nakashima K; Ubagai T; Sugimura T; Nakagama H
    Cancer Res; 2007 Oct; 67(19):9568-76. PubMed ID: 17909068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma.
    Yoo BK; Santhekadur PK; Gredler R; Chen D; Emdad L; Bhutia S; Pannell L; Fisher PB; Sarkar D
    Hepatology; 2011 May; 53(5):1538-48. PubMed ID: 21520169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SND1 binds to ERG and promotes tumor growth in genetic mouse models of prostate cancer.
    Liao SY; Rudoy D; Frank SB; Phan LT; Klezovitch O; Kwan J; Coleman I; Haffner MC; Li D; Nelson PS; Emili A; Vasioukhin V
    Nat Commun; 2023 Nov; 14(1):7435. PubMed ID: 37973913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL).
    Rajasekaran D; Jariwala N; Mendoza RG; Robertson CL; Akiel MA; Dozmorov M; Fisher PB; Sarkar D
    J Biol Chem; 2016 May; 291(20):10736-46. PubMed ID: 26997225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
    Knight JF; Shepherd CJ; Rizzo S; Brewer D; Jhavar S; Dodson AR; Cooper CS; Eeles R; Falconer A; Kovacs G; Garrett MD; Norman AR; Shipley J; Hudson DL
    Br J Cancer; 2008 Dec; 99(11):1849-58. PubMed ID: 19002168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221.
    Santhekadur PK; Das SK; Gredler R; Chen D; Srivastava J; Robertson C; Baldwin AS; Fisher PB; Sarkar D
    J Biol Chem; 2012 Apr; 287(17):13952-8. PubMed ID: 22396537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
    Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
    Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
    Kristiansen G; Fritzsche FR; Wassermann K; Jäger C; Tölls A; Lein M; Stephan C; Jung K; Pilarsky C; Dietel M; Moch H
    Br J Cancer; 2008 Sep; 99(6):939-48. PubMed ID: 18781151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors.
    Cui X; Zhang X; Liu M; Zhao C; Zhang N; Ren Y; Su C; Zhang W; Sun X; He J; Gao X; Yang J
    Genomics; 2020 Nov; 112(6):3958-3967. PubMed ID: 32645525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients.
    Li H; Yu L; Liu J; Bian X; Shi C; Sun C; Zhou X; Wen Y; Hua D; Zhao S; Ren L; An T; Luo W; Wang Q; Yu S
    Oncotarget; 2017 Mar; 8(12):19723-19737. PubMed ID: 28160566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.